Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 1

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
ulated deficit  (105,700,341)  (103,438,099)         Total Stockholders’ Equity  1,473,151   2,560,366 Total Liabilities and Stockholders’ Equity $2,807,672  $4,452,362 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3Table of Contents

ENDRA Life Sciences Inc.

Condensed Consolidated Statement of Operations

(Unaudited)

  Three Months Ended   Three Months Ended   Six Months Ended   Six Months Ended    June 30,  June 30,  June 30,  June 30,   2025  2024  2025  2024 Operating Expenses            Research and development $381,061  $716,366  $909,746  $1,757,892 Sales and marketing  68,834   162,952   137,825   401,612 General and administrative  851,195   1,351,535   1,722,801   2,851,890 Total operating expenses  1,301,090   2,230,853   2,770,372   5,011,394                  Operating loss  (1,301,090)  (2,230,853)  (2,770,372)  (5,011,394)                 Other Income (Expenses)                Other income (expense)  13,066   1,700   37,456   6,541 Warrant expense      -   -   - Changes in fair value of warrant liability  62,112   -   470,674   - Gain or Loss on settlement of warrant exercise      -   -   - Total other expenses  75,178   1,700   508,130   6,541                  Loss from operations before income taxes  (1,225,912)  (2,229,153)  (2,262,242)  (5,004,853)                 Provision for income taxes  -   -   -